Spirolactone provides protection from renal fibrosis by inhibiting the endothelial–mesenchymal transition in isoprenaline-induced heart failure in rats
Hao Zhou, Dan Xi, Jichen Liu, Jinjin Zhao, Si Chen, Zhigang Guo Division of Cardiology, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China Background: Fibrosis results in excessive accumulation of extracellular matrix p...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-05-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/spirolactone-provides-protection-from-renal-fibrosis-by-inhibiting-the-peer-reviewed-article-DDDT |
| _version_ | 1819029444900159488 |
|---|---|
| author | Zhou H Xi D Liu J Zhao J Chen S Guo Z |
| author_facet | Zhou H Xi D Liu J Zhao J Chen S Guo Z |
| author_sort | Zhou H |
| collection | DOAJ |
| description | Hao Zhou, Dan Xi, Jichen Liu, Jinjin Zhao, Si Chen, Zhigang Guo Division of Cardiology, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China Background: Fibrosis results in excessive accumulation of extracellular matrix proteins, collagen component alteration, and abnormalities in structure and is partly derived from a process called the endothelial–mesenchymal transition involving transforming growth factor β (TGF-β). We investigated whether spironolactone, an aldosterone receptor blocker, attenuated isoprenaline (Iso)-induced heart failure in rats and also studied the mechanism for the same.Methods: Sprague–Dawley rats were subcutaneously injected with Iso to induce heart failure, which promoted renal fibrosis; rats with spironolactone treatment were given a gavage of spironolactone (30 or 60 mg/kg/d, for 21 days). Cardiac function and fibrosis indices were measured. Pathological alterations and expression of Type I and III collagen, α-smooth muscle actin, cluster of differentiation-31, and TGF-β were examined.Results: In Iso-induced heart failure in rats, spironolactone significantly improved cardiac function and decreased myocardial fibrosis, reduced collagen fibrous proliferation in kidney, reduced expression of Type I and III collagen, increased the expression of cluster of differentiation-31, and decreased the expression of α-smooth muscle actin and TGF-β.Conclusion: Spironolactone may prevent renal fibrosis by inhibiting the endothelial–mesenchymal transition. Keywords: spironolactone, heart failure, renal fibrosis, endothelial–mesenchymal transition |
| first_indexed | 2024-12-21T06:14:22Z |
| format | Article |
| id | doaj.art-c52205d9c95143e2bf81bd68fe7e50cd |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-21T06:14:22Z |
| publishDate | 2016-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-c52205d9c95143e2bf81bd68fe7e50cd2022-12-21T19:13:28ZengDove Medical PressDrug Design, Development and Therapy1177-88812016-05-012016Issue 11581158826786Spirolactone provides protection from renal fibrosis by inhibiting the endothelial–mesenchymal transition in isoprenaline-induced heart failure in ratsZhou HXi DLiu JZhao JChen SGuo ZHao Zhou, Dan Xi, Jichen Liu, Jinjin Zhao, Si Chen, Zhigang Guo Division of Cardiology, Huiqiao Medical Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China Background: Fibrosis results in excessive accumulation of extracellular matrix proteins, collagen component alteration, and abnormalities in structure and is partly derived from a process called the endothelial–mesenchymal transition involving transforming growth factor β (TGF-β). We investigated whether spironolactone, an aldosterone receptor blocker, attenuated isoprenaline (Iso)-induced heart failure in rats and also studied the mechanism for the same.Methods: Sprague–Dawley rats were subcutaneously injected with Iso to induce heart failure, which promoted renal fibrosis; rats with spironolactone treatment were given a gavage of spironolactone (30 or 60 mg/kg/d, for 21 days). Cardiac function and fibrosis indices were measured. Pathological alterations and expression of Type I and III collagen, α-smooth muscle actin, cluster of differentiation-31, and TGF-β were examined.Results: In Iso-induced heart failure in rats, spironolactone significantly improved cardiac function and decreased myocardial fibrosis, reduced collagen fibrous proliferation in kidney, reduced expression of Type I and III collagen, increased the expression of cluster of differentiation-31, and decreased the expression of α-smooth muscle actin and TGF-β.Conclusion: Spironolactone may prevent renal fibrosis by inhibiting the endothelial–mesenchymal transition. Keywords: spironolactone, heart failure, renal fibrosis, endothelial–mesenchymal transitionhttps://www.dovepress.com/spirolactone-provides-protection-from-renal-fibrosis-by-inhibiting-the-peer-reviewed-article-DDDTspironolactoneheart failurerenal fibrosistransforming growth factorendothelial-mesenchymal transition |
| spellingShingle | Zhou H Xi D Liu J Zhao J Chen S Guo Z Spirolactone provides protection from renal fibrosis by inhibiting the endothelial–mesenchymal transition in isoprenaline-induced heart failure in rats Drug Design, Development and Therapy spironolactone heart failure renal fibrosis transforming growth factor endothelial-mesenchymal transition |
| title | Spirolactone provides protection from renal fibrosis by inhibiting the endothelial–mesenchymal transition in isoprenaline-induced heart failure in rats |
| title_full | Spirolactone provides protection from renal fibrosis by inhibiting the endothelial–mesenchymal transition in isoprenaline-induced heart failure in rats |
| title_fullStr | Spirolactone provides protection from renal fibrosis by inhibiting the endothelial–mesenchymal transition in isoprenaline-induced heart failure in rats |
| title_full_unstemmed | Spirolactone provides protection from renal fibrosis by inhibiting the endothelial–mesenchymal transition in isoprenaline-induced heart failure in rats |
| title_short | Spirolactone provides protection from renal fibrosis by inhibiting the endothelial–mesenchymal transition in isoprenaline-induced heart failure in rats |
| title_sort | spirolactone provides protection from renal fibrosis by inhibiting the endothelial ndash mesenchymal transition in isoprenaline induced heart failure in rats |
| topic | spironolactone heart failure renal fibrosis transforming growth factor endothelial-mesenchymal transition |
| url | https://www.dovepress.com/spirolactone-provides-protection-from-renal-fibrosis-by-inhibiting-the-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT zhouh spirolactoneprovidesprotectionfromrenalfibrosisbyinhibitingtheendothelialndashmesenchymaltransitioninisoprenalineinducedheartfailureinrats AT xid spirolactoneprovidesprotectionfromrenalfibrosisbyinhibitingtheendothelialndashmesenchymaltransitioninisoprenalineinducedheartfailureinrats AT liuj spirolactoneprovidesprotectionfromrenalfibrosisbyinhibitingtheendothelialndashmesenchymaltransitioninisoprenalineinducedheartfailureinrats AT zhaoj spirolactoneprovidesprotectionfromrenalfibrosisbyinhibitingtheendothelialndashmesenchymaltransitioninisoprenalineinducedheartfailureinrats AT chens spirolactoneprovidesprotectionfromrenalfibrosisbyinhibitingtheendothelialndashmesenchymaltransitioninisoprenalineinducedheartfailureinrats AT guoz spirolactoneprovidesprotectionfromrenalfibrosisbyinhibitingtheendothelialndashmesenchymaltransitioninisoprenalineinducedheartfailureinrats |